专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2648760A4 SMART POLYMERIC NANOPARTICLES WHICH OVERCOME MULTIDRUG RESISTANCE TO CANCER CHEMOTHERAPEUTICS AND TREATMENT-RELATED SYSTEMIC TOXICITY 审中-公开
标题翻译：智能的聚合物纳米粒子克服多重耐药性癌症的治疗和相关的治疗系统毒性
公开(公告)号：EP2648760A4
公开(公告)日：2015-09-16
申请号：EP11847391
申请日：2011-12-08
申请人： UNIV JOHNS HOPKINS
发明人： MAITRA ANIRBAN , PRAMANIK DIPANKAR
IPC分类号： A61K47/48 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/12 , A61K31/704 , A61K31/7042 , A61K45/06 , A61P35/00 , C08F20/06 , C08F20/56 , C08F220/06 , C08F220/56 , C08F226/10
CPC分类号： A61K31/12 , A61K9/0019 , A61K9/5138 , A61K31/704 , A61K31/7042 , A61K45/06 , C08F220/06 , C08F220/56 , C08F226/10 , A61K2300/00

2. 发明公开

EP2780473A4 DIFFERENTIAL IDENTIFICATION OF PANCREATIC CYSTS 有权
标题翻译：孢囊区分性鉴定
公开(公告)号：EP2780473A4
公开(公告)日：2016-02-17
申请号：EP12849091
申请日：2012-11-12
申请人： UNIV JOHNS HOPKINS
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , PAPADOPOULOS NICKOLAS , WU JIAN , HRUBAN RALPH , MAITRA ANIRBAN , DAL MOLIN MARCO
IPC分类号： C12Q1/68 , C12N15/11
CPC分类号： C12Q1/6886 , C12Q1/6883 , C12Q2600/156

3. 发明专利

AU2007333528A1 Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles 未知
公开(公告)号：AU2007333528A1
公开(公告)日：2008-06-19
申请号：AU2007333528
申请日：2007-10-05
申请人： UNIV JOHNS HOPKINS
发明人： BISHT SAVITA , MAITRA ANIRBAN , FELDMANN GEORG
IPC分类号： A61K47/30
摘要： Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropylacrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpryolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivatives like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%; and acrylic acid (AA), at a molar ration of about 10% to about 30%.

4. 发明公开

EP2073848A4 WATER-DISPERSIBLE ORAL, PARENTERAL, AND TOPICAL FORMULATIONS FOR POORLY WATER SOLUBLE DRUGS USING SMART POLYMERIC NANOPARTICLES 有权
标题翻译：分散于水中口服，注射和重水溶性药物聪明的聚合物纳米微粒外用制剂
公开(公告)号：EP2073848A4
公开(公告)日：2011-06-29
申请号：EP07871123
申请日：2007-10-05
申请人： UNIV JOHNS HOPKINS
发明人： MAITRA ANIRBAN , FELDMANN GEORG , BISHT SAVITA
IPC分类号： A61K47/30 , A61K9/51 , A61K47/48
CPC分类号： A61K9/146 , A61K9/19 , A61K9/5138 , A61K47/6933 , A61K47/6935 , B01J13/14 , B01J13/18 , B82Y5/00

5. 发明公开

EP1996182A4 CANCER TREATMENT WITH GAMMA-SECRETASE INHIBITORS 审中-公开
标题翻译：癌症治疗用γSEKRETASEHEMMERN
公开(公告)号：EP1996182A4
公开(公告)日：2009-08-12
申请号：EP07752086
申请日：2007-02-27
申请人： UNIV JOHNS HOPKINS
发明人： EBERHART CHARLES , FAN XING , MAITRA ANIRBAN
IPC分类号： A61K31/38 , A61P35/00
CPC分类号： C07D333/34 , A61K31/38 , A61K31/381 , A61K31/5513 , A61K45/06 , A61N5/10 , C07D409/12

6. 发明申请

WO03030725A3 PANCREATIC CANCER DIAGNOSIS AND THERAPIES 审中-公开
标题翻译：胰腺癌诊断和治疗
公开(公告)号：WO03030725A3
公开(公告)日：2003-10-09
申请号：PCT/US0232714
申请日：2002-10-11
申请人： UNIV JOHNS HOPKINS , HRUBAN RALPH H , ARGANI PEDRAM , IACOBUZIO-DONAHUE CHRISTINE , MAITRA ANIRBAN
发明人： HRUBAN RALPH H , ARGANI PEDRAM , IACOBUZIO-DONAHUE CHRISTINE , MAITRA ANIRBAN
IPC分类号： A61B20060101 , A61K48/00 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention includes methods and systems for identification (diagnosis) of abnormal cell growth by analysis of a patient sample, particularly the presence of a pancreatic cancer or susceptibility to a pancreatic cancer. The invention also includes therapeutic agents for treating pancreatic cancers as well as methods for identifying candidate agents for treatment of pancreatic cancers.
摘要翻译：本发明包括通过分析患者样品，特别是胰腺癌的存在或对胰腺癌的易感性来鉴定（诊断）异常细胞生长的方法和系统。本发明还包括治疗胰腺癌的治疗剂以及鉴定用于治疗胰腺癌的候选试剂的方法。

7. 发明申请

WO2012178034A2 MUTATIONS IN PANCREATIC NEOPLASMS 审中-公开
标题翻译：胰腺神经细胞的突变
公开(公告)号：WO2012178034A2
公开(公告)日：2012-12-27
申请号：PCT/US2012043783
申请日：2012-06-22
申请人： UNIV JOHNS HOPKINS , VOGELSTEIN BERT , KINZLER KENNETH W , WU JIAN , DIAZ LUIS , PAPADOPOULOS NICKOLAS , MATTHAEI HANNO , HRUBAN RALPH , MAITRA ANIRBAN
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , WU JIAN , DIAZ LUIS , PAPADOPOULOS NICKOLAS , MATTHAEI HANNO , HRUBAN RALPH , MAITRA ANIRBAN
IPC分类号： C12Q1/68 , C12N15/11
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/156
摘要： To help reveal the pathogenesis of these lesions, we purified the DNA from Intraductal Papillary Mucinous Neoplasm (IPMN) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of GNAS. We found that GNAS mutations were present in 66% of IPMNs and that either KRAS or GNAS mutations could be identified in 96%. In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations. In seven of these eight cases, the GNAS mutations present in the IPMNs were also found in the invasive lesion. GNAS mutations were not found in other types of cystic neoplasms of the pancreas or in invasive adenocarcinomas not associated with IPMNs. These data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions.
摘要翻译：为了揭示这些病变的发病机制，我们从19名患者的导管内乳头状粘液性肿瘤（IPMN）囊肿液中纯化DNA，并搜索了在人类癌症中通常改变的169种基因中的突变。我们在GNAS的201号密码子处鉴定了复发性突变。我们发现GNAS突变存在于66％的IPMNs中，KRAS或GNAS突变可以在96％中鉴定。在8例中，我们可以研究与含有GNAS突变的IPMN相关的侵袭性腺癌。在这8例中有7例中，存在于IPMNs中的GNAS突变也在侵袭性损伤中发现。在其他类型的胰腺囊性肿瘤或与IPMN无关的侵袭性腺癌中未发现GNAS突变。这些数据表明，GNAS突变可以为囊性胰腺病变患者的诊断和治疗提供依据。

8. 发明申请

WO2008073558A2 WATER-DISPERSIBLE ORAL, PARENTERAL, AND TOPICAL FORMULATIONS FOR POORLY WATER SOLUBLE DRUGS USING SMART POLYMERIC NANOPARTICLES 审中-公开
标题翻译：使用智能聚合物纳米颗粒的水溶性难溶性药物的水分散性口服，肠胃外和局部用制剂
公开(公告)号：WO2008073558A2
公开(公告)日：2008-06-19
申请号：PCT/US2007080536
申请日：2007-10-05
申请人： UNIV JOHNS HOPKINS , MAITRA ANIRBAN , FELDMANN GEORG , BISHT SAVITA
发明人： MAITRA ANIRBAN , FELDMANN GEORG , BISHT SAVITA
IPC分类号： A61K47/48 , A61K9/19 , A61K47/32
CPC分类号： A61K9/146 , A61K9/19 , A61K9/5138 , A61K47/6933 , A61K47/6935 , B01J13/14 , B01J13/18 , B82Y5/00
摘要： Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropyl acrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpyrolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivatives like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%;, and acrylic acid (AA), at a molar ratio of about 10% to about 30%. The formed nanoparticles may be optionally surface functional using reactive groups present in AA, including PEGylation, or conjugation of moieties such as chemotherapeutics, contrasting agents, antibodies, radionucleides, ligands, and sugars, for diagnostic, therapeutic, and imaging purposes. The polymeric nanoparticles are preferably dispersed in aqueous solutions. The polymeric nanoparticles incorporate one or more types of medicines or bioactive agents in the hydrophobic core; on occasion, the medicine or bioactive agent may be conjugated to the nanoparticle surface via reactive functional groups. The polymeric nanoparticles are capable of delivering the said medicines or bioactive agents through oral, parenteral, or topical routes. The polymeric nanoparticles allow poorly water soluble medicines or bioactive agents, or those with poor oral bioavailability, to be formulated in an aqueous solution, and enable their convenient delivery into the systemic circulation.
摘要翻译：具有疏水性芯和亲水性壳的聚合物纳米颗粒由1）N-异丙基丙烯酰胺（NIPAAM）以约50％至约90％，优选60％的摩尔比用于特定递送途径如口服或肠胃外 ; 或水溶性乙烯基衍生物如乙烯基吡咯烷酮（VP）或乙酸乙烯酯（VA）或水不溶性乙烯基衍生物如甲基丙烯酸甲酯（MMA）或苯乙烯（ST），摩尔比为约10％至约30％;和丙烯酸（AA）以约10％至约30％的摩尔比混合。为了诊断，治疗和成像目的，所形成的纳米颗粒可以使用存在于AA中的反应基团（包括聚乙二醇化）或部分（例如化学治疗剂，造影剂，抗体，放射性核素，配体和糖）的缀合来任选表面功能。聚合物纳米粒子优选分散在水溶液中。聚合物纳米粒子在疏水性核心中掺入一种或多种类型的药物或生物活性剂; 有时，药物或生物活性剂可以通过反应性官能团与纳米颗粒表面缀合。聚合物纳米颗粒能够通过口服，肠胃外或局部途径递送所述药物或生物活性剂。聚合物纳米颗粒允许水溶性差的药物或生物活性剂或口服生物利用度差的那些配制在水溶液中，并使其能够方便地输送到体循环中。

9. 发明专利

AU2002342053A1 Pancreatic cancer diagnosis and therapies 未知
公开(公告)号：AU2002342053A1
公开(公告)日：2003-04-22
申请号：AU2002342053
申请日：2002-10-11
申请人： UNIV JOHNS HOPKINS
发明人： MAITRA ANIRBAN , IACOBUZIO-DONAHUE CHRISTINE , HRUBAN RALPH H , ARGANI PEDRAM
IPC分类号： A61B20060101 , A61K48/00 , C12Q1/68

10. 发明公开

EP2723896A4 MUTATIONS IN PANCREATIC NEOPLASMS 有权
标题翻译：突变胰腺肿瘤
公开(公告)号：EP2723896A4
公开(公告)日：2015-02-18
申请号：EP12802288
申请日：2012-06-22
申请人： UNIV JOHNS HOPKINS
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , WU JIAN , DIAZ LUIS , PAPADOPOULOS NICKOLAS , MATTHAEI HANNO , HRUBAN RALPH , MAITRA ANIRBAN
IPC分类号： C12Q1/68 , C12N15/11
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/156
摘要： To help reveal the pathogenesis of these lesions, we purified the DNA from Intraductal Papillary Mucinous Neoplasm (IPMN) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of GNAS. We found that GNAS mutations were present in 66% of IPMNs and that either KRAS or GNAS mutations could be identified in 96%. In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations. In seven of these eight cases, the GNAS mutations present in the IPMNs were also found in the invasive lesion. GNAS mutations were not found in other types of cystic neoplasms of the pancreas or in invasive adenocarcinomas not associated with IPMNs. These data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式